RESEARCH PAPER
Viral load suppression among patients receiving antiretroviral therapy in outpatient clinics in Democratic Republic of Congo
 
More details
Hide details
1
Division of Global HIV and Tuberculosis, CDC, Atlanta, GA, USA
 
2
Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA, USA
 
3
FHI 360, Washington, DC, USA
 
4
FHI 360, Democratic Republic of Congo
 
5
National AIDS Control Program (PNLS), Democratic Republic of Congo
 
 
Submission date: 2021-08-11
 
 
Final revision date: 2022-02-23
 
 
Acceptance date: 2022-02-25
 
 
Publication date: 2023-09-15
 
 
HIV & AIDS Review 2023;22(3):198-203
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Education and disease management have resulted in global decline of new HIV infections, from 2.8 million a year in 2000 to about 1.5 million in 2020 (46% reduction) as well as number of deaths, from 1.4 million in 2000 to 690,000 a year in 2020 (51% reduction). The purpose of this study was to examine factors associated with viral load (VL) suppression (< 1,000 copies/ml), including age, sex, and geographic and clinical characteristics of patients on antiretroviral therapy (ART) in outpatient clinics in Kinshasa and Haut-Katanga Provinces, Democratic Republic of Congo (DRC).

Material and methods:
Using a retrospective cohort study design, we analyzed data of 5,338 people living with HIV (PLHIV) on ART from 116 HIV/AIDS clinics located in the Haut-Katanga and Kinshasa Provinces in DRC. 2 and multivariable logistic regression analyses were applied.

Results:
Age and urban health zones were significantly associated with VL suppression. Eighty-six percent of adult patients (15 years or older) had achieved a VL suppression, compared to 73.5% of patients younger than 15 years. Average time on ART was less than three years, and majority of participants were 15 years of age or older, females, and mostly living in urban areas.

Conclusions:
Our findings indicated that younger patients on ART and patients living in semi-rural areas (vs. urban) had a significantly lower probability of risk of VL suppression, underscoring the need for enhanced efforts targeting these populations.

 
REFERENCES (30)
1.
Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27: 973-979. doi: 10.1097/QAD.0b013e32835cae9c.
 
2.
Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-19. doi: 10.1086/505147.
 
3.
UNAIDS. UNAIDS Global HIV Statistics: Fact Sheet 2021. Geneva 2021. https://www.unaids.org/sites/d... [Accessed: 24.06.2021].
 
4.
UNAIDS. Democratic Republic of Congo. Democratic Republic of the Congo on track with its HIV catch-up plan. Geneva 2017. https://www.unaids.org/en/reso... [Accessed: 30.04.2021].
 
5.
Insight Start Study Group; Lundgren J, Babiker A, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807. doi: 10.1056/nejmoa1506816.
 
6.
Gamell A, Letang E, Jullu B, et al. Uptake of guidelines on prevention of mother-to-child transmission of HIV in rural Tanzania: time for change. Swiss Med Wkly 2013; 143: w13775. doi: 10.4414/smw.2013.13775.
 
7.
World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd ed. WHO, Geneva 2016.
 
8.
Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society – USA panel. JAMA 2020; 324: 1651-1669. doi: 10.1001/jama.2020.17025.
 
9.
Stolka K, Iriondo-Perez J, Kiumbu M, et al. Characteristics of anti¬retroviral therapy-naïve patients lost-to-care in HIV clinics in Democratic Republic of Congo, Cameroon, and Burundi. AIDS Care 2016; 28: 913-918. doi: 10.1080/09540121.2015.1124982.
 
10.
Mehta KG, Baxi R, Patel S, Parmar M. Drug adherence rate and loss to follow-up among people living with HIV/AIDS attending an ART Centre in a Tertiary Government Hospital in Western India. J Family Med Prim Care 2016; 5: 266-269. doi: 10.4103/2249-4863.192325.
 
11.
Crim S, Tie Y, Beer L, Weiser J, Dasgupta S. Barriers to antiretroviral therapy adherence among HIV-positive Hispanic and Latino men who have sex with men – United States, 2015-2019. MMWR Morb Mortal Wkly Rep 2020; 69: 1437-1442. doi: 10.15585/mmwr.mm6940a1.
 
12.
Genberg BL, Lee Y, Rogers WH, Wilson IB. Four types of barriers to adherence of antiretroviral therapy are associated with decreased adherence over time. AIDS Behav 2015; 19: 85-92. doi: 10.1007/s10461-014-0775-2.
 
13.
Centers for Disease Control and Prevention. Treatment, Care, and Prevention for People with HIV. Talking To Your Patients: ART Adherence. Atlanta 2019. https://www.cdc.gov/hiv/clinic... [Accessed: 15.04.2021].
 
14.
Adejumo OA, Malee KM, Ryscavage P, Hunter SJ, Taiwo BO. Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review. J Int AIDS Soc 2015; 18: 20049. doi: 10.7448/IAS.18.1.20049.
 
15.
Damulira C, Mukasa MN, Byansi W, et al. Examining the relationship of social support and family cohesion on ART adherence among HIV-positive adolescents in southern Uganda: baseline findings. Vulnerable Child Youth Stud 2019; 14: 181-190. doi: 10.1080/17450128.2019.1576960.
 
16.
Mburu G, Hodgson I, Kalibala S, et al. Adolescent HIV disclosure in Zambia: barriers, facilitators and outcomes. J Int AIDS Soc 2014; 17: 18866. doi: 10.7448/IAS.17.1.18866.
 
17.
Fetzer BC, Mupenda B, Lusiama J, Kitetele F, Golin C, Behets F. Barriers to and facilitators of adherence to pediatric antiretroviral therapy in a sub-Saharan setting: insights from a qualitative study. AIDS Patient Care STDS 2011; 25: 611-621. doi: 10.1089/apc.2011.0083.
 
18.
Young S, Wheeler AC, McCoy SI, Weiser SD. A review of the role of food insecurity in adherence to care and treatment among adult and pediatric populations living with HIV and AIDS. AIDS Behav 2013; 18 (Suppl 5): 505-515. doi: 10.1007/s10461-013-0547-4.
 
19.
The Lancet HIV. The syndemic threat of food insecurity and HIV. Lancet HIV 2020; 7: e75. doi: 10.1016/s2352-3018(20)30004-7.
 
20.
Office of AIDS Research. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. ClinicalInfo.hiv.gov. Bethesda 2020. https://clinicalinfo.hiv.gov/s... [Accessed: 16.04.2021].
 
21.
Kaishusha Mupendwa B, Kadima Ntokamunda J. Treatment adhesion and factors affecting it at the Kadutu Clinic (Democratic Republic of the Congo). Cahiers de Santé 2009; 19: 205-215. doi: 10.1684/san.2009.0178.
 
22.
Wadunde I, Tuhebwe D, Ediau M, Okure G, Mpimbaza A, Wanyenze RK. Factors associated with adherence to antiretroviral therapy among HIV infected children in Kabale district, Uganda: a cross sectional study. BMC Res Notes 2018; 11: 466. doi: 10.1186/s13104-018-3575-3.
 
23.
Ammon N, Mason S, Corkery JM. Factors impacting antiretroviral therapy adherence among human immunodeficiency virus-positive adolescents in Sub-Saharan Africa: a systematic review. Public Health 2018; 157: 20-31. doi: 10.1016/j.puhe.2017.12.010.
 
24.
Hudelson C, Cluver L. Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low-and middle-income countries: a systematic review. AIDS Care 2015; 27: 805-816. doi: 10.1080/09540121.2015.1011073.
 
25.
Sumbi E, Venables E, Harrison R, et al. “It’s a secret between us”: a qualitative study on children and care-giver experiences of HIV disclosure in Kinshasa, Democratic Republic of Congo. BMC Public Health 2021; 21: 313. doi: 10.1186/s12889-021-10327-5.
 
26.
Tchouwa GF, Eymard-Duvernay S, Cournil A, et al. Nationwide Estimates of Viral Load Suppression and Acquired HIV Drug Resistance in Cameroon. EClinicalMedicine 2018; 1: 21-27. doi: 10.1016/j.eclinm.2018.06.005.
 
27.
Palk L, Okano J, Dullie L, Blower S. Travel time to health-care facilities, mode of transportation, and HIV elimination in Malawi: a geospatial modelling analysis. Lancet Glob Health 2020; 8: e1555-e1564. doi: 10.1016/s2214-109x(20)30351-x.
 
28.
Boullé C, Guichet E, Kouanfack C, et al. Virologic failure and human immunodeficiency virus drug resistance in rural cameroon with regard to the UNAIDS 90-90-90 treatment targets. Open Forum Infect Dis 2016; 3: ofw233. doi: 10.1093/ofid/ofw233.
 
29.
Ingle SM, May M, Uebel K, et al. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS 2010; 24: 2717-2725. doi: 10.1097/QAD.0b013e32833fb71f.
 
30.
Chirambo L, Valeta M, Banda Kamanga T, Nyondo-Mipando A. Factors influencing adherence to antiretroviral treatment among adults accessing care from private health facilities in Malawi. BMC Public Health 2019; 19: 1382. doi: 10.1186/s12889-019-7768-z.
 
eISSN:1732-2707
ISSN:1730-1270
Journals System - logo
Scroll to top